29 Aug 2024Open access4cites
Novel Plasmodium falciparum histidine-rich protein 2/3 repeat type in Ethiopian malaria infection: does this affect performance of HRP2-based malaria RDT?Publisher siteMalaria Journal, Malaria Research and Control
Active, last published 2026
Aynalem
Mandefro
Scholar“Research profile drawn from open scholarly records.”
Addis Ababa University
Ethiopia
Claim Your ProfileEthiopia3
H-index
51
Citations
Aynalem has not officially claimed their profile. If you are Aynalem, claim it free.
Claim Your Profile
Pioneer
LOCKED
Pathfinder
LOCKED
Scholar
EARNED
Innovator
LOCKED
Inventor
LOCKED
Catalyst
LOCKED
Expert
UPGRADE
01 · About the work
What I study
research summary for Aynalem Mandefro will appear here once their profile is updated.
02 · Reach
Publication output and reach
Aynalem's work has been cited 51 times across 1 active year. Bars show publications per year; the line shows cumulative citation totals across publications first appearing in each year.
04 · Where I am
Affiliations
Affiliation on published researchAddis Ababa University, EthiopiaDrawn from the institution listed on this researcher’s published work.
Research themes (UN SDGs)
05 · Selected work
Recent publications
3 works17 Apr 2024Open access33cites
Widespread pfhrp2/3 deletions and HRP2-based false-negative results in southern EthiopiaPublisher siteMalaria Journal, Genomics and Rare Diseases
23 Jan 2024Open access14cites
Analysing the six-year malaria trends at Metehara Health Centre in Central Ethiopia: the impact of resurgence on the 2030 elimination goalsPublisher siteMalaria Journal, Malaria Research and Control
Expert Academic Profiles go further
Citation trend analytics, exportable publication records, and direct enquiry routing from industry and funders.
Are you Aynalem?
Claim it to verify your details, connect with industry partners, and explore Fractional Domain Expert opportunities through MARATTO™.
African researchers are full of potential that too often goes unrecognised. Your MARATTO™ profile gives your work the commercial pathway it deserves.
Claim Your Profile
Free to claim · takes a minute to verify it’s you